ARVO 2024: Non-invasive testing could use tear film to screen for changes in Huntington Disease

News
Article

The mutant huntingtin protein in tear fluid may have the potential to serve as an early marker of changes in Huntington disease

A single tear on a person's face. Image credit: ©Chepko Danil – stock.adobe.com

The non-invasive method uses mutant huntingtin protein levels to screen for changes in the disease. Image credit: ©Chepko Danil – stock.adobe.com

Results from a new study indicate the mutant huntingtin (mHTT) protein in the tear fluid may serve as an early and non-invasive marker of changes in Huntington disease. First author Marlies Gijs, PhD, from the University Eye Clinic Maastricht, Universiteit Maastricht, Maastricht, Limburg, the Netherlands, reported her group’s findings at the Association of Vision in Research and Ophthalmology (ARVO) in Seattle.

Huntington disease (HD), an autosomal-dominant, fully-penetrant, neurodegenerative disease that most commonly affects adults during middle age, results from CAG repeat expansion in the HTT gene, resulting in the expression of mHTT protein, Gijs explained.

In this first-of-a-kind study, she and her colleagues set out to detect and quantify mHTT in the tear fluid. They recruited 20 manifest and 13 premanifest HD gene expansion carriers (HDGECs) and 20 age-matched controls. All patients were assessed using the Unified Huntington Disease Rating Scale (UHDRS) total motor score (TMS) and total function capacity score.

The tear fluid samples were collected using Schirmer strips. Proteins were extracted by elution and centrifugation and the tear mHTT was determined using the Single Molecule Counting SMCxPRO technology.

Tear fluid results

The level of protein in the tear fluid far exceeded that of normal controls. “The average tear mHTT levels in manifest (67,223 ± 80,360 fM) and premanifest patients (55,561 ± 45,931 fM) were significantly (p < 0.001) higher than in healthy controls (1,622 ± 2179 fM). We noted significant correlations between tear mHTT levels and CAG repeat length, estimated years to diagnosis, disease burden score, and UHDRS TMS,” the investigators reported.

The receiver operating characteristic curve demonstrated an almost perfect score (area under the curve [AUC] = 0.9975) when comparing controls to manifest patients, which indicated a test providing the correct answer 99.75% of the time. In like manner, the AUC between controls and premanifest patients was 0.9846. The optimal cut-off value (= highest Youden index) to distinguish between controls and manifest patients was 4,544 fM, whereas it was 6,596 fM for the distinction between controls and premanifest patients, the author reported.

“The detection of high levels of mHTT in tear fluid from HDGECs in our study endorses that tear fluid is a valuable source for HD biomarkers. Ultimately, tear biomarkers could help the HD community to non-invasively measure the effectiveness of disease-modifying drugs and determine the optimal time and dose to start such therapies,” Gijs and colleagues concluded.

Reference:

1. Gijs M, Joma N, Datson N, et al. Detection of high levels of mutant huntingtin protein in tear fluid of patients with Huntington’s Disease. Paper presented at: Association for Research in Vision and Ophthalmology annual meeting; May 5-9, 2024; Seattle, WA. Presentation number: 3322

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.